This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bednarek, A. Articles by Aldaz, C. M. Search for Related Content PubMed PubMed Citation Articles by Bednarek, A. Articles by Aldaz, C. M.

Increased Telomerase Activity in Mouse Skin Premalignant Progression¹

Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957

It has been postulated that the expression of the ribonucleoprotein telomerase is necessary to overcome cellular senescence and that malignant tumors must express telomerase to maintain their immortality. In most human adult tissues, telomerase activity is not detected. In contrast, several murine tissues express various levels of telomerase. Mouse skin however, does not show telomerase activity. Using the mouse skin chemical carcinogenesis system, a well-characterized model for studying premalignant and malignant progression, we assayed telomerase activity at various stages of premalignant papilloma progression by means of the recently developed telomeric repeat amplification protocol. We observed that at 10 weeks of promotion, only one mouse skin papilloma of 11 analyzed showed high levels of telomerase activity. The number of papillomas showing higher levels of telomerase activity increased at 20 weeks, and at 30 weeks of promotion, 100% of papillomas expressed significantly higher levels of telomerase. We learned from previous studies that early papillomas are diploid, well-differentiated lesions, whereas late papillomas are aneuploid and very dysplastic. It appears that the progressive increase in telomerase activity is associated with the increased level of genomic instability and the phenotypic progression of these premalignant tumors. It is also possible, however, that the increase in telomerase activity could be in part a consequence of an increase in the proportion of proliferating cells. Nevertheless, the mouse skin system may be a very useful in vivo model for the study and development of anti-telomerase therapeutic strategies.

¹ Supported in part by NIH Grant CA57596-03S1.

² To whom requests for reprints should be addressed, at Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, P.O. Box 398, Smithville, Texas 78957.

Received 7/14/95. Accepted 8/29/95.

This article has been cited by other articles:

				J. M. Ritz, O. Kuhle, S. Riethdorf, B. Sipos, W. Deppert, C. Englert, and C. Gunes A Novel Transgenic Mouse Model Reveals Humanlike Regulation of an 8-kbp Human TERT Gene Promoter Fragment in Normal and Tumor Tissues Cancer Res., February 15, 2005; 65(4): 1187 - 1196. [Abstract] [Full Text] [PDF]

				J. Ohno, Y. Horio, Y. Sekido, Y. Hasegawa, M. Takahashi, J.-i. Nishizawa, H. Saito, F. Ishikawa, and K. Shimokata Telomerase activation and p53 mutations in urethane-induced A/J mouse lung tumor development Carcinogenesis, May 1, 2001; 22(5): 751 - 756. [Abstract] [Full Text] [PDF]

				K.-W. Chang, S. Sarraj, S.-C. Lin, P.-I Tsai, and D. Solt p53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis Carcinogenesis, July 1, 2000; 21(7): 1441 - 1451. [Abstract] [Full Text] [PDF]

				T. Günther, R. Schneider-Stock, C. Häckel, M. Pross, H.-U. Schulz, H. Lippert, and A. Roessner Telomerase Activity and Expression of hTRT and hTR in Gastrointestinal Stromal Tumors in Comparison with Extragastrointestinal Sarcomas Clin. Cancer Res., May 1, 2000; 6(5): 1811 - 1818. [Abstract] [Full Text]

				S. Y. Rha, E. Izbicka, R. Lawrence, K. Davidson, D. Sun, M. P. Moyer, G. D. Roodman, L. Hurley, and D. Von Hoff Effect of Telomere and Telomerase Interactive Agents on Human Tumor and Normal Cell Lines Clin. Cancer Res., March 1, 2000; 6(3): 987 - 993. [Abstract] [Full Text]

				A. Bednarek, A. Shilkaitis, A. Green, R. Lubet, G. Kelloff, K. Christov, and C. M. Aldaz Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors Carcinogenesis, May 1, 1999; 20(5): 879 - 883. [Abstract] [Full Text] [PDF]

				S. Kondo, Y. Tanaka, Y. Kondo, M. Hitomi, G. H. Barnett, Y. Ishizaka, J. Liu, T. Haqqi, A. Nishiyama, B. Villeponteau, et al. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation FASEB J, July 1, 1998; 12(10): 801 - 811. [Abstract] [Full Text]

				C. W. Greider Telomerase activity, cell proliferation, and cancer PNAS, January 6, 1998; 95(1): 90 - 92. [Full Text] [PDF]

				P. M. Lansdorp Lessons from Mice without Telomerase J. Cell Biol., October 20, 1997; 139(2): 309 - 312. [Full Text] [PDF]